MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Regeneron Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

599.49 1.95

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

582.49

Max

600.82

Galvenie mērījumi

By Trading Economics

Ienākumi

-423M

918M

Pārdošana

69M

3.8B

P/E

Sektora vidējais

14.641

57.333

EPS

12.07

Dividenžu ienesīgums

0.63

Peļņas marža

24.219

Darbinieki

15,106

EBITDA

-534M

1.1B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+50.6% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.63%

2.63%

Nākamie ieņēmumi

2025. g. 29. apr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-13B

62B

Iepriekšējā atvēršanas cena

597.54

Iepriekšējā slēgšanas cena

599.49

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

Regeneron Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 4. febr. 12:13 UTC

Peļņas

Regeneron 4Q Revenue Up on Strong Sales of EYLEA HD

2025. g. 22. apr. 10:51 UTC

Top Ziņas

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs -- WSJ

2025. g. 28. febr. 12:00 UTC

Top Ziņas

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

2025. g. 4. febr. 11:58 UTC

Peļņas

Regeneron 4Q Rev Up on Strong Sales of EYLEA HD

2025. g. 4. febr. 11:37 UTC

Peļņas

Regeneron Pharma Sees 2025 Adjusted R&D $5B-$5.2B >REGN

2025. g. 4. febr. 11:37 UTC

Peļņas

Regeneron Pharma Sees 2025 Gross Margin on Net Product Sales 87%-88% >REGN

2025. g. 4. febr. 11:36 UTC

Peļņas

Regeneron Pharma Sees 2025 Capital Spending $850M-$975M >REGN

2025. g. 4. febr. 11:35 UTC

Peļņas

Regeneron Pharma Declares Initial Quarterly Dividend of 88c >REGN

2025. g. 4. febr. 11:35 UTC

Peļņas

Regeneron Pharma 4Q Adj EPS $12.07 >REGN

2025. g. 4. febr. 11:34 UTC

Peļņas

Regeneron Pharma 4Q U.S. Net Sales for Eylea HD, Eylea Rose 2% to $1.5B >REGN

2025. g. 4. febr. 11:34 UTC

Peļņas

Regeneron Pharma: 4Q Dupixent Global Net Sales Recorded by Sanofi Rose 15% to $3.7B >REGN

2025. g. 4. febr. 11:32 UTC

Peļņas

Regeneron Pharma Board OKs Additional $3 Billion Share Repurchase >REGN

2025. g. 4. febr. 11:31 UTC

Peļņas

Regeneron Pharma Initiates Quarterly Cash Dividend Program >REGN

2025. g. 31. janv. 08:30 UTC

Iegādes, apvienošanās, pārņemšana

It's Bananas, but Stock Splits Can Pay Off. Here Are 5 Likely Contenders. -- Barrons.com

2025. g. 28. janv. 10:30 UTC

Top Ziņas

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

2024. g. 31. okt. 13:58 UTC

Peļņas

Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom -- IBD

2024. g. 31. okt. 10:52 UTC

Peļņas

Regeneron Earnings Top Views For Biotech Giant -- IBD

2024. g. 31. okt. 10:34 UTC

Peļņas

Regeneron Pharma 3Q Adj EPS $12.46 >REGN

2024. g. 31. okt. 10:33 UTC

Peļņas

Regeneron Pharma 3Q EPS Cut 43c by Acquired IPR&D Charge >REGN

2024. g. 31. okt. 10:33 UTC

Peļņas

Regeneron Pharma 3Q U.S. Sales for Eylea HD, Eylea Rose 3% to $1.54B >REGN

2024. g. 31. okt. 10:32 UTC

Peļņas

Regeneron Pharma: 3Q Dupixent Global Net Sales Recorded by Sanofi Rose 23% to $3.82B >REGN

2024. g. 31. okt. 10:30 UTC

Peļņas

Regeneron Pharma 3Q Rev $3.72B >REGN

2024. g. 31. okt. 10:30 UTC

Peļņas

Regeneron Pharma 3Q EPS $11.54 >REGN

2024. g. 31. okt. 10:30 UTC

Peļņas

Regeneron Pharma 3Q Net $1.34B >REGN

2024. g. 25. okt. 20:25 UTC

Peļņas

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

2024. g. 1. aug. 11:50 UTC

Peļņas

Regeneron Stock Climbs After Strong Second-Quarter Performance -- IBD

2024. g. 1. aug. 10:37 UTC

Peļņas

Regeneron Pharma 2Q Adj EPS $11.56 >REGN

2024. g. 1. aug. 10:30 UTC

Peļņas

Regeneron Pharma 2Q EPS $12.41 >REGN

2024. g. 1. aug. 10:30 UTC

Peļņas

Regeneron Pharma 2Q Net $1.43B >REGN

2024. g. 1. aug. 10:30 UTC

Peļņas

Regeneron Pharma 2Q Rev $3.55B >REGN

Salīdzinājums

Cenas izmaiņa

Regeneron Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

50.6% augšup

Prognoze 12 mēnešiem

Vidējais 881.75 USD  50.6%

Augstākais 1,120 USD

Zemākais 547 USD

Pamatojoties uz 21 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Regeneron Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

21 ratings

17

Pirkt

3

Turēt

1

Pārdot

Tehniskais rādītājs

By Trading Central

554.18 / N/AAtbalsts un pretestība

Īstermiņā

Strong Bullish Evidence

Vidējā termiņā

Weak Bullish Evidence

Ilgtermiņā

Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.